Abstract. – Hydroxyurea is a cytotoxic agent widely used in the treatment of myeloproliferative disorders. It is considered a well-tolerated antineoplastic drug, with a dose-related bone marrow suppression as main adverse effect. This report describes a patient with essential thrombocytopenia who developed an interstitial pneumonitis and respiratory failure within 4 years from beginning therapy with hydroxyurea (HU). After discontinuing of HU, both clinical and radiological resolution of pneumonitis occurred. In conclusion, HU-induced pulmonary toxicity is a potentially life-threatening side effect.

Key Words: Interstitial pneumonitis, Hydroxyurea, Pulmonary toxicity.

Introduction

Several chemotherapy drugs have been associated with pulmonary toxicity including busulphan, bleomycin, chlorambucil, cyclophosphamide, cytosine arabinoside, melphalan, methotrexate, mitomycin and procarbazine1,2. Hydroxyurea (HU), a ribonucleotide reductase inhibitor, has been increasingly utilized, rather than busulphan, to control myeloproliferative disorders, mainly because of its relative lack of severe adverse effects3. Apart from dose-related bone marrow suppression, this antineoplastic agent is generally well tolerated. Fever and pulmonary side effects as hydroxyurea-induced acute alveolitis are extremely rare4,5. We report a case of interstitial pneumonitis in a patient treated with HU for essential thrombocytopenia.

Case Report

A 77-year-old woman was admitted to our Hospital because of severe dyspnoea and respiratory failure. His past medical history included pleurisy in young age and cholecystectomy due to symptomatic gallstones. Four years before admission, she was referred to a hematologist for increased platelet count (700,000/ml). After confirmation of high platelet count she underwent bone marrow biopsy, which demonstrated essential thrombocytopenia, according to Polycythemia Vera Study Group (PVSG) diagnostic criteria6. Investigation for JAK2 mutation showed positive results. After a first period of 1 year treatment with aspirin (100 mg/daily), platelet count started to rise progressively up to 1,000,000 mm³. Treatment with HU was then established at a dose of 500 mg/daily. In the following 3 weeks platelet count returned almost at normal values (425,000 mm³). One month before admission in our Hospital, the patient presented progressive dyspnoe and dry cough and was treated by the general practitioner with levofloxacin 750 mg/daily and prednisolone 40 mg/daily without clinical improvement. At admission, blood pressure and pulse rate were within the normal limits; the patient was afebrile. Chest examination revealed bilateral fine crackles at lung bases. Arterial blood gas analysis, on room air, showed type I respiratory failure (PaO₂ 59 mmHg, PaCO₂ 38 mmHg, pH 7.42, HCO₃ - 24.6 mmol/l) and oxygen therapy was promptly started. Chest X-Ray showed multiple bilateral opacities, flowing together at both lung bases. Routine blood test, including serum autoimmunity screening, were negative. Cultures from blood and sputum were negative. Serological searches for viral infection (Varicella-zoster, CMV, Herpes simplex 1, Herpes simplex 2, Adenovirus) and for bacteria (Legionella pneumophila, Mycoplasma pneumoniae, Chlamydia pneumoniae) were negative. HRCT scan of the chest revealed fine honeycombning, more evident at lung bases and in the subpleuric zones, and small areas of ground-glass at the upper lobes (Figure 1). Lung function tests showed a restrictive pattern: TLC 3.62 l (72% predicted), DLco/VA 51% predicted. Bronchoscopy
Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature

Figure 1. HRCT scan images (axial and coronal). Diffuse reticular opacities are present predominantly at the lung bases. At the same level, diffuse interstitial thickening more evident at the left lung.

with bronchoalveolar lavage fluid (BALF) was then performed. Analysis of BALF revealed: 350,000 cells mm³ (78% macrophages, 20% neutrophils, 2% eosinophils). Bacterioscopic and cultural tests for bacteria, fungi and *M. tuberculosis* on BALF were all negative. HU was discontinued and N-Acetyl-Cysteine was started (600 mg 3 times/day). Prednisone treatment was progressively tapered within 3 weeks. At two-months follow-up, a significant improvement in symptoms and HRCT scan findings (Figure 2) were observed. In addition, arterial blood gas analysis on room air showed a significant improvement: PaO₂ 78 mmHg, PaCO₂ 39 mmHg, pH 7.42, HCO₃⁻ 25 mmol/l. Lung function tests improved as well: TLC 4.1 l (82% predicted), DLCO/VA 70% predicted. At one year follow-up, a further reduction in lung abnormalities at HRCT scan was noticed.

Discussion

Wong et al⁷ described a unique case of HU-induced pneumonitis after prolonged drug exposure; clinical symptoms and radiological signs of pulmonary toxicity developed after 2 years of HU treatment. Only 6 other cases of HU-induced alveolitis or interstitial pneumonitis, with an acute or a subacute onset, have been reported in the literature⁴,⁵,⁸-¹¹. To the best of our knowledge, this report represents the first case in which clinical symptoms and radiological signs developed 4 years from HU initial treatment. An infectious and/or an immunologic etiology of the interstitial pneumonitis was excluded, on the basis of the serologic and microbiological tests. The improvement in the clinical status and in the laboratory and instrumental findings associated to the discontinuation of HU treatment speaks in favor of a drug induced lung toxicity.

HU is a ribonucleotide reductase inhibitor. The mechanism of action is based on its reduction of production of deoxyribonucleotides via inhibition of the enzyme ribonucleotide reductase by scavenging tyrosyl free radicals as they are involved in the reduction of nucleoside diphosphates¹². It is used principally in myeloproliferative disorders as polycythemia vera and essential thrombocytosis but also in sickle cell disease, associated with antiretroviral therapy in AIDS, and in psoriasis as second line therapy¹³-¹⁶. HU main side effect is a dose-related bone mar-
row suppression. Other side effects include gastrointestinal symptoms, stomatitis, impairment of renal tubular function, dysuria, transient elevation of hepatocellular enzymes, alopecia and rash. HU-induced pulmonary toxicity is extremely rare: literature reported cases consists mainly of acute alveolitis or interstitial pneumonitis. Interstitial lung disease may be related to infective or autoimmune diseases, environmental exposure, radiations, aspiration or idiopathic. In our patient, HRCT findings were compatible with a diagnosis of interstitial pneumonitis, likely evolving into pulmonary fibrosis. An infectious cause was excluded, and an autoimmune nature was also ruled out. Also other possible causes of interstitial pneumonitis, such as environmental exposure or radiotherapy were excluded. The dramatic clinical and instrumental improvement after HU discontinuation and steroids tapering strongly support the diagnosis of drug induced lung injury. In the literature, previous cases of HU induced interstitial pneumonitis were also treated with HU cessation alone or with the addition of steroids, which can have a role in hastening resolution of ground-glass infiltrates associated with active inflammation. In our case, together with the discontinuation of HU therapy, steroids treatment was also discontinued to avoid possible confounding effects.

Conclusions

Drug induced interstitial pneumonia should be considered in patients under HU and presenting with respiratory symptoms, such as exertional dyspnoea. HU-induced interstitial pneumonitis can occur even after several years from initial treatment. If not diagnosed, HU-induced interstitial pneumonitis may lead to respiratory failure and lung fibrosis.

Conflict of Interest

The Authors declare that there are no conflicts of interest.

References

Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature

3) **Dorr RT, Von Hoff DD.** Cancer chemotherapy handbook. 2nd ed. Norwalk, CT: Appleton & Lange 1994.


